No Data
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Sinolink: Pharmaceutical sector under pressure in the early stage, reversal in 2025 comes from three major opportunities.
With the continuous aging of the population, stable expansion of residents' medical consumption, and the continuous recovery of industry diagnosis and treatment volume, the long-term growth logic of the medical industry remains clear, and the overall foundation is stable.
Are Strong Financial Prospects The Force That Is Driving The Momentum In Xiamen Amoytop Biotech Co., Ltd.'s SHSE:688278) Stock?
Sinolink Securities: Pharmaceutical prosperity in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the healthcare sector, changes in the consumer environment, and some medical insurance cost control policies still being implemented, the business climate continued to bottom out in the Q3 report, with a slower rebound than expected.
Additional Considerations Required While Assessing Xiamen Amoytop Biotech's (SHSE:688278) Strong Earnings
Xiamen Amoytop Biotech Q3 Profit Up 50%, Revenue Rises 38%
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today
